MK-1167 + diltiazem

MK-1167 + diltiazem is an experimental combination of two drugs: **MK-1167**, a novel small-molecule positive allosteric modulator of the α7 nicotinic acetylcholine receptor currently in clinical development for Alzheimer's disease dementia, and **diltiazem**, a well-established calcium channel blocker used in cardiovascular conditions. Clinical pharmacology studies have specifically tested the pharmacokinetic and safety profile of MK-1167 when co-administered with diltiazem, primarily to evaluate possible drug-drug interactions, as diltiazem is a moderate CYP3A4 inhibitor and may influence the metabolism of investigational agents like MK-1167. This combination is not a therapeutic regimen but reflects a research setting for interaction studies and safety assessment[2][7].